Core Viewpoint - Amgen is expected to exceed earnings expectations for the fourth quarter and full year 2024, with a consensus estimate of $8.84 billion in sales and $5.01 per share in earnings [1] Group 1: Sales Performance - Strong volume growth is anticipated for Amgen's products, including Evenity, Repatha, Prolia, Kyprolis, and Blincyto, although prices are expected to decline due to increased rebates [2] - The Zacks Consensus Estimate for sales of Prolia, Repatha, Evenity, and Blincyto is $1.18 billion, $551 million, $413 million, and $339 million, respectively [2] - Estimates for Prolia, Repatha, and Evenity sales are $1.05 billion, $542.9 million, and $418.3 million, respectively, with Tezspire and Tavneos contributing $274.4 million and $102.9 million to top-line growth [3] Group 2: New Product Launches - The U.S. launch of Imdelltra for advanced small cell lung cancer is progressing well, with a 200% sequential growth in the third quarter, expected to continue into the fourth quarter [4] - Tepezza sales are projected to be flat to slightly down, with efforts to reorganize and expand the sales force targeting low clinical activity score patients [6] Group 3: Financial Estimates - The Zacks Consensus Estimate for Otezla is $611 million, while the estimate for Enbrel is $861 million, with Amgen's estimates being $605.4 million and $874.5 million, respectively [5] - Adjusted EPS for the fourth quarter is expected to be lower than the third quarter due to historically high R&D costs [7] Group 4: Pipeline Developments - Updates on the pipeline candidate MariTide for obesity are anticipated, with recent phase II study results showing an average weight loss of approximately 20% over 52 weeks, which fell short of investor expectations [8] Group 5: Earnings Surprise History - Amgen has a strong earnings surprise history, with an average surprise of 4.10% over the last four quarters, although the stock has declined 10.6% over the past year [10]

Company Overview - Amgen is one of the largest biotech companies globally, with a strong presence in various therapeutic areas including oncology, cardiovascular disease, and neuroscience [12] - The company has developed successful drugs such as Epogen and Neupogen, and has launched next-generation products like Aranesp and Neulasta [12] - Amgen's acquisition of Immunex Corporation provided access to the blockbuster drug Enbrel, although older drugs are facing declining sales due to competition [12] Financial Performance - Amgen has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position in the market [13] - The company has a Value Style Score of B, supported by a forward P/E ratio of 13.66, which is attractive for value investors [13] - For fiscal 2024, the Zacks Consensus Estimate for earnings has increased by $0.05 to $19.56 per share, with an average earnings surprise of 4.1% [13] Investment Potential - With a solid Zacks Rank and top-tier Value and VGM Style Scores, Amgen is recommended for investors' consideration [14]

Core Viewpoint - Amgen is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2024, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Amgen's quarterly earnings is $5.01 per share, reflecting a year-over-year increase of 6.4% [3]. - Revenues are projected to reach $8.84 billion, which is a 7.9% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.17%, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Amgen is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of 3.15% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Amgen currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Amgen exceeded the expected earnings of $5.11 per share by delivering $5.58, resulting in a surprise of 9.20% [12]. - Over the past four quarters, Amgen has consistently beaten consensus EPS estimates [13]. Conclusion - While Amgen is positioned as a strong candidate for an earnings beat, other factors should also be considered when evaluating the stock ahead of its earnings release [16].

Core Viewpoint - Amgen (AMGN) has shown a strong performance recently, with a return of +4.9% over the past month, outperforming the S&P 500 composite's +1.1% change, indicating potential positive momentum for the stock [2]. Earnings Estimate Revisions - For the current quarter, Amgen is expected to report earnings of $5.01 per share, reflecting a year-over-year increase of +6.4%. However, the Zacks Consensus Estimate has decreased by -3.6% in the last 30 days [5]. - The consensus earnings estimate for the current fiscal year stands at $19.56, indicating a year-over-year change of +4.9%, with a slight increase of +0.7% over the past month [5]. - For the next fiscal year, the consensus estimate is $20.52, also showing a +4.9% change from the previous year, with a +0.7% increase in the last month [6]. Revenue Growth Projections - Amgen's consensus sales estimate for the current quarter is $8.84 billion, indicating a year-over-year growth of +7.9%. The estimates for the current and next fiscal years are $33.18 billion and $34.31 billion, reflecting changes of +17.7% and +3.4%, respectively [9]. Last Reported Results - In the last reported quarter, Amgen achieved revenues of $8.5 billion, representing a year-over-year increase of +23.2%. The EPS for this period was $5.58, compared to $4.96 a year ago [10]. - The reported revenues were slightly below the Zacks Consensus Estimate of $8.51 billion, resulting in a surprise of -0.04%. However, the EPS exceeded expectations by +9.2% [11]. Valuation Metrics - Amgen is graded B in the Zacks Value Style Score, indicating that it is trading at a discount compared to its peers [15]. - The evaluation of Amgen's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), suggests that the stock may be undervalued relative to its historical values and peers [13][14]. Conclusion - The current Zacks Rank of 3 suggests that Amgen may perform in line with the broader market in the near term, despite the mixed signals from earnings estimates and valuation metrics [16].

Stock Performance - Amgen's stock ended the recent trading session at $277 88, showing a +1 62% increase from the previous day's closing price [1] - The stock outperformed the S&P 500, which gained 0 53%, while the Dow gained 0 93% and the Nasdaq added 0 22% [1] - Over the past month, Amgen's shares gained 3 38%, outperforming the Medical sector's 1 49% gain and the S&P 500's 2 69% gain [1] Earnings and Revenue Projections - Amgen's upcoming earnings report is scheduled for February 4, 2025, with projected earnings per share (EPS) of $5 01, reflecting a 6 37% increase from the same quarter last year [2] - Revenue is expected to be $8 84 billion, indicating a 7 86% increase compared to the same quarter of the previous year [2] Analyst Estimates and Valuation Metrics - Recent shifts in analyst projections for Amgen indicate changing near-term business trends, with upbeat changes reflecting a favorable outlook on the company's business health and profitability [3] - The Zacks Consensus EPS estimate has moved 0 43% higher within the past month, and Amgen currently holds a Zacks Rank 3 (Hold) [5] - Amgen's Forward P/E ratio is 13 36, representing a discount compared to the industry average of 23 22 [6] - The company's PEG ratio is 2 78, higher than the industry average of 1 36, reflecting its expected earnings growth trajectory [7] Industry Performance - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 74, placing it in the top 30% of all 250+ industries [8] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Scientists at deCODE genetics and Amgen have created a comprehensive map of human DNA recombination, enhancing the understanding of genetic diversity and its implications for health and fertility [1][2][3] Group 1: Research Findings - The new recombination map is the first to include shorter-scale shuffling of grandparental DNA, which is challenging to detect due to high sequence similarity [3] - The map identifies regions of DNA that lack significant reshuffling, likely to safeguard critical genetic functions and prevent chromosomal issues [3] - The research highlights that errors in the recombination process can lead to reproductive challenges, contributing to infertility affecting approximately 10% of couples globally [4] Group 2: Gender Differences - The study reveals distinct patterns of genome recombination between men and women, with women experiencing fewer non-crossover recombinations that increase with age, potentially explaining higher risks of pregnancy complications in older mothers [5] - Men do not exhibit age-related changes in recombination frequency, although both sexes can pass mutations to their offspring [5] Group 3: Evolutionary Implications - Understanding the recombination process is crucial for insights into human evolution and individual health differences, as all human genetic diversity stems from recombination and de novo mutations [6] - The map indicates that mutations are more frequent near regions of DNA mixing, suggesting a strong correlation between recombination and mutation processes [6] Group 4: Company Background - deCODE genetics, based in Reykjavik, Iceland, is a leader in human genome analysis and has identified genetic risk factors for numerous common diseases [7] - The company's goal is to leverage genetic insights to develop new diagnostic, treatment, and prevention methods for diseases [7]

Core Viewpoint - Amgen's KRAS inhibitor, Lumakras, has received FDA approval for use in combination with Vectibix for treating KRAS G12C-mutated metastatic colorectal cancer, marking a significant advancement in targeted therapy for this patient population [1][3]. Group 1: Product Approval and Clinical Data - The FDA approved Lumakras in combination with Vectibix for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously undergone chemotherapy [1]. - The approval was based on the phase III CodeBreaK 300 study, which demonstrated superior progression-free survival (PFS) for the Lumakras and Vectibix combination compared to standard-of-care treatments [3][4]. - The study evaluated two doses of Lumakras (960 mg daily or 240 mg daily) and showed favorable overall survival and overall response rates as key secondary endpoints [5]. Group 2: Market Performance and Sales - In the first nine months of 2024, Lumakras generated sales of $265 million, reflecting a year-over-year increase of 30.5% [7]. - Amgen's shares have decreased by 12.2% over the past year, slightly better than the industry decline of 14.1% [2]. Group 3: Future Prospects and Studies - Ongoing label expansion studies for Lumakras aim to broaden the addressable patient population, which could significantly enhance future sales [7]. - Amgen is also exploring Lumakras in phase I and II studies for non-small cell lung cancer (NSCLC), both as a monotherapy and in combination with other therapies, which may lead to additional approvals [8].

Company Performance - Amgen's stock closed at $272.11, with a daily increase of 0.99%, underperforming the S&P 500 which gained 1% [1] - Over the past month, Amgen's shares increased by 3.15%, outperforming the Medical sector's decline of 1.36% and the S&P 500's drop of 2.14% [1] Upcoming Earnings - Amgen is set to release its earnings on February 4, 2025, with an expected EPS of $5.02, reflecting a growth of 6.58% year-over-year [2] - The consensus estimate for quarterly revenue is $8.85 billion, indicating a 7.92% increase compared to the same quarter last year [2] Analyst Estimates - Changes in analyst estimates for Amgen are crucial as they often reflect short-term business dynamics, with positive revisions signaling a favorable business outlook [3] Valuation Metrics - Amgen has a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 13.23, which is lower than the industry average of 21.97 [5] - The company has a PEG ratio of 2.75, compared to the industry average of 1.43, indicating a higher expected earnings growth rate relative to its price [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 56, placing it in the top 23% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOCTHOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, ox ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.So, a company being near its 52-week low is no reason to avoid it. On the contrary, that might be the best time to invest, provided there are good reasons to believe it will bounce back.With that in mind, let's consider two stocks that haven't performed ...